Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Kersey

Physician Assistant Savannah, TN Physician Assistant

NPI 1881954329 CMS profile 11133507

765 Florence Rd, Savannah, TN 38372

Open in the dashboard

General payments

$398,668

882 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Kersey of Savannah, TN is reported in the CMS Open Payments database as having received $398,668 across 882 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $66,496 164
2024 General $82,345 186
2023 General $112,762 247
2022 General $84,613 176
2021 General $52,451 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Kersey
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Anna Kersey were reported at $66,496. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Anna Kersey Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $52,451 $132 $37–$438 $132
2022 $84,613 $155 $48–$522 $149
2023 $112,762 $167 $52–$557 $160
2024 $82,345 $178 $55–$600 $164
2025 $66,496 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $389,456 825 payments
  2. Axsome Therapeutics, Inc. $6,240 7 payments
  3. Allergan Inc. $1,915 5 payments
  4. Avanir Pharmaceuticals, Inc. $180 11 payments
  5. Otsuka America Pharmaceutical, Inc. $168 8 payments
  6. Alexion Pharmaceuticals, Inc. $135 1 payment
  7. Novartis Pharmaceuticals Corporation $128 6 payments
  8. Amgen Inc. $104 2 payments
  9. Lundbeck LLC $86 4 payments
  10. Biohaven Pharmaceuticals, Inc. $57 2 payments
  11. Other $200 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $336,325 214 payments
  2. Travel and Lodging $41,273 214 payments
  3. Food and Beverage $15,569 452 payments
  4. Honoraria $5,500 2 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $311,442 639 payments
  2. QULIPTA $226,299 490 payments
  3. Symbravo $6,240 7 payments
  4. NUEDEXTA pseudobulbar affect (PBA) $180 11 payments
  5. EVENITY $104 2 payments
  6. VRAYLAR $93 7 payments
  7. NUEDEXTA Neurology $92 5 payments
  8. LEQVIO $85 4 payments
  9. REXULTI $76 3 payments
  10. NURTEC ODT $71 3 payments
  11. Other $462 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

2,882

Median for Physician Assistant: 241

Drug cost

$122,719

Median for Physician Assistant: $4,110

Branded share of claims

17.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 24 $24,935
Xarelto Rivaroxaban Brand 22 $20,940
Farxiga Dapagliflozin Propanediol Brand 24 $20,589
Eliquis Apixaban Brand 22 $12,710
Breo Ellipta Fluticasone/Vilanterol Brand 13 $11,140
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 76 $2,393
Gabapentin Generic 184 $1,668
Omeprazole Generic 115 $1,396
Synthroid Levothyroxine Sodium Brand 26 $1,326
Albuterol Sulfate Hfa Albuterol Sulfate Brand 41 $1,089

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$84,488

Of which drugs: $1,666

Medicare patients

252

Average age 76

Services billed

3,388

171 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 34%
Ischemic heart disease 25%
Atrial fibrillation 21%
Osteoporosis 19%
COPD 18%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 65 65 $1,392
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 1,180 $114
Injection, ceftriaxone sodium, per 250 mg J0696 Office 26 225 $73
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 40 $33
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 33 138 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $42,914
$42,914 — —
UBRELVY
  • AbbVie, Inc. $39,206
$39,206 — —
REXULTI
  • Lundbeck LLC $53
  • Otsuka America Pharmaceutical, Inc. $23
$77 — —
VRAYLAR
  • AbbVie, Inc. $53
$53 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

882 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record